18 mei 2020: als update van onderstaande studie is de volgende studie interessant: 


In de PDF worden verschillende manieren aangegeven om bepaalde tumorexpressie en DNA mutaties geschikt voor toepassen van immuuntherapie bij verschillende vormen van kanker op een rijtje gezet. 

13 maart 2018: Bron: The Journal of Nuclear Medicin

Bristol-Myers Squibb, de producent van o.a. nivolumab, heeft een weinig belastende manier gevonden om vast te stellen of een kankerpatiënt voldoende P1-L1 expressie heeft om de kans op het aanslaan van immuuntherapie met een anti-PD medicijn te doen slagen. 

Aan een petscan wordt een stofje, Novel 18F-Labeled Adnectin geheten, toegevoegd die de PD-L1 expressie laat oplichten op het oppervlak van de tumorcellen. Het is nog maar een muizenstudie maar ik begrijp uit het persbericht (zie odneraan artikel) dat in ieder geval Bristol-Meyers Squibb deze manier van meten snel gaat gebruiken.

Klik op de titel van de studie voor het volledige studierapport (persbericht staat onderaan dit artikel: Synthesis and Biologic Evaluation of a Novel 18F-Labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression


Representative whole-body PET (maximal-intensity projection) images 90 min after injection of (A) 18F-BMS-986192 only and (B) 18F-BMS-986192 with a coadministration of 1 mg/kg BMS-986192 in the same monkey. (C) Representative anti–PD-L1 immunohistochemistry of healthy monkey spleen tissue.


A novel 18F-labeled adnectin radioligand was developed for PET imaging of PD-L1–expressing tissues. In addition, an improved methodology was described based on a unique prosthetic group that allows for the 18F labeling of adnectins under mild conditions. Using copper-free click chemistry, we generated 18F-BMS-986192 with picomolar affinity toward the human PD-L1 receptor in high radiochemical purity and high specific activity. This methodology addresses important issues associated with the 18F labeling of proteins and should be applicable to related systems. In vivo imaging demonstrated rapid delivery of 18F-BMS-986192 to PD-L1–expressing tumors and rapid clearance from non-PD-L1–expressing tumors and tissues. 18F-BMS-986192 was highly stable in vivo and had low background signals in organs of interest such as the lung. The results of this study demonstrate the feasibility of preparing 18F anti–PD-L1 adnectins for the measurement of PD-L1 expression in tumors. Radiation dosimetry estimates indicate that this tracer is safe to administer in human studies. Clinical studies with 18F-BMS-986192 are currently under way to better understand this checkpoint pathway and PD-L1 expression in human tumors.

Hier het persbericht over deze studie:

Researchers develop new approach that uses single PET scan to personalize cancer treatment

RESTON, Va. - Researchers have developed a same-day, noninvasive positron emission tomography (PET)-based imaging approach to assess PD-L1 positive tumors, and the study is presented in the featured article of The Journal of Nuclear Medicine's March issue.

A healthy immune system strikes a delicate balance between eradicating infections and cancers and not overreacting to damage one's own tissue. Immune checkpoints help control the immune response, but tumors exploit these checkpoint pathways by expressing special proteins that evade antitumor immune responses. One major checkpoint inhibitor pathway is the PD-1 pathway, and its ligand is PD-L1.

In this study, the PD-L1 ligand, which enables cancer to evade a person's immune system, has been successfully targeted for the first time with a fluorine-18 (18F)-labeled PD-L1 radioligand. Until now, efforts to predict response to treatments targeting PD-1 or PD-L1 have typically been limited to evaluation of a single patient biopsy sample.

"This approach represents an opportunity for physicians to noninvasively assess all of a patient's tumors for PD-L1 expression with a single PET scan and timely readout," explains David J. Donnelly, PhD, at Bristol-Myers Squibb Research and Development in Princeton, New Jersey. "This may help guide treatment decisions and assess treatment response, to help identify the right treatment for the right patient at the right time and right dose."

For the study, an anti-PD-L1 adnectin (an engineered, target-binding protein) was labeled with 18F to generate 18F-BMS-986192, which was then evaluated in mice bearing bilateral PD-L1(-) and PD-L1(+) subcutaneous tumors. 18F-BMS-986192 was also evaluated for distribution, binding and radiation dosimetry in healthy cynomolgus monkey. The results of the study demonstrate the feasibility of the approach, and the radiation dosimetry estimates indicate that the tracer is safe to administer in human studies. Clinical studies are now underway to measure PD-L1 expression in human tumors.


Authors of "Synthesis and Biological Evaluation of a Novel 18F-labeled Adnectin as a PET Radioligand for Imaging PD-L1 Expression" include David J. Donnelly, R. Adam Smith, Paul Morin, Daša Lipovšek, Jochem Gokemeijer, Daniel Cohen, Virginie Lafont, Tritin Tran, Erin L. Cole, Martin Wright, Joonyoung Kim, Adrienne Pena, Daniel Kukral, Douglas D. Dischino, Patrick Chow, Jinping Gan, Olufemi Adelakun, Xi-Tao Wang, Kai Cao, David Leung, Samuel J. Bonacorsi, Jr., and Wendy Hayes, Bristol-Myers Squibb Research and Development, Princeton, New Jersey.


The Society of Nuclear Medicine and Molecular Imaging (SNMMI) is an international scientific and medical organization dedicated to raising awareness about nuclear medicine and molecular imaging, vital elements of precision medicine that allow diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.

SNMMI's more than 15,000 members set the standard for molecular imaging and nuclear medicine practice by creating guidelines, sharing information through journals and meetings and leading advocacy on key issues that affect molecular imaging and therapy research and practice. For more information, visit http://www.snmmi.org.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

  • Published online Oct. 12, 2017.


  1. 1.
  2. 2.
  3. 3.
  4. 4.
  5. 5.
  6. 6.
  7. 7.
  8. 8.
  9. 9.
  10. 10.
  11. 11.
  12. 12.
  13. 13.
  14. 14.
  15. 15.
  16. 16.
  17. 17.
  18. 18.
  19. 19.
  20. 20.
  21. 21.
  22. 22.
  23. 23.
  24. 24.
  25. 25.
  26. 26.
  27. 27.
  28. 28.
  29. 29.
  30. 30.
  31. 31.
  32. 32.
  • Received for publication July 31, 2017.
  • Accepted for publication September 19, 2017.

Plaats een reactie ...

Reageer op "Een petscan met Novel 18F-Labeled Adnectin kan direct laten zien of een kankerpatient voldoende PD-L1 Expressie heeft voor immuuntherapie met anti-PD medicijnen"

Gerelateerde artikelen

Gerelateerde artikelen

Photo Immuno Therapy (PIT) >> Coley vaccin: Immuuntherapie >> Darmschimmels - darmbacterien >> Een petscan met Novel 18F-Labeled >> Het voordeel van immunotherapeutische >> Het menselijk immuunsysteem >> Immuuntherapie bij kanker: >> Immuuntherapie met behulp >> NLR meting - veranderende >> Oncolytische virussen geven >>